They found that TLR2 is a potential therapeutic target for the prevention and treatment of AML, and they suggested the prototype, Pep2-D(KLAKLAK)2 as a promising drug candidate in the treatment of AML 28. The gene discussed is TLR2; the disease is acute myeloid leukemia.